These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 12559642)

  • 21. The management of interim analyses in drug development.
    Facey KM; Lewis JA
    Stat Med; 1998 Aug 15-30; 17(15-16):1801-9; discussion 1811-2. PubMed ID: 9749448
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Termination of a randomized controlled trial of two vasectomy techniques.
    Chen-Mok M; Bangdiwala SI; Dominik R; Hays M; Irsula B; Sokal DC
    Control Clin Trials; 2003 Feb; 24(1):78-84. PubMed ID: 12559645
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Some practical aspects of the interim monitoring of clinical trials.
    Simon R
    Stat Med; 1994 Jul 15-30; 13(13-14):1401-9. PubMed ID: 7973219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Data and safety monitoring during randomized controlled trials of nursing interventions.
    Artinian NT; Froelicher ES; Vander Wal JS
    Nurs Res; 2004; 53(6):414-8. PubMed ID: 15586138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of interim data and Data Monitoring Committee recommendations in randomized controlled trial reports: frequency, implications and potential sources of bias.
    Tharmanathan P; Calvert M; Hampton J; Freemantle N
    BMC Med Res Methodol; 2008 Mar; 8():12. PubMed ID: 18366697
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preliminary data release for randomized clinical trials of noninferiority: a new proposal.
    Korn EL; Hunsberger S; Freidlin B; Smith MA; Abrams JS
    J Clin Oncol; 2005 Aug; 23(24):5831-6. PubMed ID: 16027441
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Applications of Bayesian statistical methodology to clinical trial design: A case study of a phase 2 trial with an interim futility assessment in patients with knee osteoarthritis.
    Smith CL; Jin Y; Raddad E; McNearney TA; Ni X; Monteith D; Brown R; Deeg MA; Schnitzer T
    Pharm Stat; 2019 Jan; 18(1):39-53. PubMed ID: 30321909
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An analysis of protocols and publications suggested that most discontinuations of clinical trials were not based on preplanned interim analyses or stopping rules.
    Stegert M; Kasenda B; von Elm E; You JJ; Blümle A; Tomonaga Y; Saccilotto R; Amstutz A; Bengough T; Briel M;
    J Clin Epidemiol; 2016 Jan; 69():152-60. PubMed ID: 26361993
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reporting on data monitoring committees in neonatal randomised controlled trials is inconsistent.
    Perrem LM; Gosling S; Ravikumar I; Khashan AS; Miletin J; Ryan CA; Dempsey E
    Acta Paediatr; 2017 Jan; 106(1):30-33. PubMed ID: 27637413
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An introduction to the use of interim data analyses in clinical trials.
    Lewis RJ
    Ann Emerg Med; 1993 Sep; 22(9):1463-9. PubMed ID: 8363121
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monitoring and reporting of the Women's Health Initiative randomized hormone therapy trials.
    Anderson GL; Kooperberg C; Geller N; Rossouw JE; Pettinger M; Prentice RL
    Clin Trials; 2007; 4(3):207-17. PubMed ID: 17715246
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The independent statistician for data monitoring committees.
    DeMets DL; Fleming TR
    Stat Med; 2004 May; 23(10):1513-7. PubMed ID: 15122729
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Information time scales for interim analyses of randomized clinical trials.
    Freidlin B; Othus M; Korn EL
    Clin Trials; 2016 Aug; 13(4):391-9. PubMed ID: 27136947
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulatory perspectives on data monitoring.
    O'Neill RT
    Stat Med; 2002 Oct; 21(19):2831-42. PubMed ID: 12325099
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Data monitoring and interim analyses in the pharmaceutical industry: ethical and logistical considerations.
    Rockhold FW; Enas GG
    Stat Med; 1993 Mar; 12(5-6):471-9. PubMed ID: 8493425
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning.
    Schmidt R; Burkhardt B; Faldum A
    Methods Inf Med; 2015; 54(5):434-46. PubMed ID: 26429500
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The data and safety monitoring board and acquired immune deficiency syndrome (AIDS) clinical trials.
    DeMets DL; Fleming TR; Whitley RJ; Childress JF; Ellenberg SS; Foulkes M; Mayer KH; O'Fallon J; Pollard RB; Rahal JJ
    Control Clin Trials; 1995 Dec; 16(6):408-21. PubMed ID: 8720018
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Designs for efficient clinical trials.
    Simon R
    Oncology (Williston Park); 1989 Jul; 3(7):43-9; discussion 51-3. PubMed ID: 2701811
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Children's Oncology Group routinely applies "lack of efficacy" interim monitoring to its randomized clinical trials.
    Anderson JR; Krailo M
    Am J Bioeth; 2011 Mar; 11(3):18-9. PubMed ID: 21400379
    [No Abstract]   [Full Text] [Related]  

  • 40. Independence of the statistician who analyses unblinded data.
    Siegel JP; O'Neill RT; Temple R; Campbell G; Foulkes MA
    Stat Med; 2004 May; 23(10):1527-9. PubMed ID: 15122732
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.